GCLC and osteogenesis imperfecta: We hypothesize that OI can prevent VS induced by the D66H‐type mutation and may mediate the protection via activating the KEAP1‐NRF2‐GCLC/HO‐1 signalling pathway based on study findings of OI in other disease models.